Elsevier

Brain Research

Volume 633, Issues 1–2, 7 January 1994, Pages 337-342
Brain Research

Short communication
Effect of phenycyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study

https://doi.org/10.1016/0006-8993(94)91558-XGet rights and content

Abstract

The effect of phencyclidine (PCP) on the extracellular dopamine levels in the rat prefrontal cortex was investigated using an in vivo brain dialysis technique. PCP increased extracellular dopamine levels in the prefrontal cortex of freely-moving rats after the systemic (7.5 mg/kg i.p.) or the local injection (100 μM and 500 μM). The local injection of MK-801, which is a more selective and potent NMDA receptor antagonist than PCP also increased the extracellular dopamine levels (from 10 μM to 100 μM). These results suggest that part of the effect of PCP is attributable to its antagonistic effect on the NMDA receptor.

References (40)

  • OhmoriT. et al.

    Effect of phencyclidine on spontaneous and N-methyl-D-aspartate (NMDA)-induced efflux of dopamine from superfused slices of rat striatum

    Neuropharmacology

    (1992)
  • RaoT.S. et al.

    Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptors

    Neuropharmacology

    (1990)
  • SmithR.C. et al.

    Effect of phencyclidine on3H-catecholamine and3H-serotonin uptake in synaptosomal preparations from rat brain

    Biochem. Pharmacol.

    (1977)
  • SnellL.D. et al.

    Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release

    Eur. J. Pharmacol.

    (1988)
  • SteinpreisR.E. et al.

    The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study

    Brain Res.

    (1993)
  • TaniiY. et al.

    Phencyclidine increases extracellular dopamine metabolites in rat medial frontal cortex as measured by in vivo dialysis

    Neurosci. Lett.

    (1990)
  • AbercrombieE.D. et al.

    Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens and medial prefrontal cortex

    J. Neurochem.

    (1989)
  • BowyerJ.F. et al.

    Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes

    J. Pharmacol. Exp. Ther.

    (1984)
  • CarlssonA.

    The current status of the dopamine hypothesis of schizophrenia

    Neuropsychopharmacology

    (1989)
  • CarterC.J. et al.

    Differential control byN-methyl-D-aspartate and kainate of striatal dopamine release in vivo: a trans-striatal dialysis study

    J. Neurochem.

    (1988)
  • Cited by (118)

    • Effects of post-training administration of LY341495, as an mGluR2/3 antagonist on spatial memory deficit in rats fed with high-fat diet

      2020, IBRO Reports
      Citation Excerpt :

      Group II receptors are located mainly in presynaptic terminals (Cartmell and Schoepp, 2000) and are highly expressed in CNS areas related to learning and memory, such as the hippocampus, amygdala, and prefrontal cortex (PFC) (Ohishi et al., 1993a, b). Moreover, cognitive enhancement has been observed after treatment with metabotropic glutamate receptor 2/3 antagonists and glutamatergic blockade in some studies (Gargiulo et al., 2005; Hondo et al., 1994). The present study, therefore further explored the effects of metabotropic glutamate receptor 2/3 manipulation on cognitive performance.

    • Chronic phencyclidine treatment induces long-lasting glutamatergic activation of VTA dopamine neurons

      2014, Neuroscience Letters
      Citation Excerpt :

      Systematic/peripheral administration of PCP is reported to increase firing of dopamine neurons in the ventral tegmental area (VTA) [2]. The change in VTA dopamine neuron activities induced by PCP is considered to be associated with increase of dopamine release in terminal regions of mesolimbic dopamine pathway [3–7]. The increase of dopamine release is considered to be related to symptoms such as increase of locomotor activity which can be seen in PCP administered animals [6,7].

    View all citing articles on Scopus

    This study was partly supported by a research grant (2A-7) for Nervous and Mental Disorders from the Ministry of Health and Welfare, Japan.

    View full text